# US 2008/0075719 A1 · Method for Augmenting B Cell Depletion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075719 A1
- Document ID: US20080075719A1
- Status: Published application
- Kind: A1
- Application number: 11/862,176
- Filed: 2007-09-26
- Published: 2008-03-27
- Earliest claimed: 2004-04-16
- Assignees: Genentech, Inc.
- Inventors: Andrew Chan; Qian Gong; Flavius Martin
- Web page: https://patentgrep.com/patent/US20080075719A1

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 39/39541: {against normal tissues, cells}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/08: Vasodilators for multiple indications
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods of augmenting B cell depletion by promoting intravascular access of B cell subsets sequestered in lymphoid tissues rendering the B cells sensitive to killing mediated by the B cell depleting agent. One method of promoting intravascular access is by the use of integrin antagonists. Methods of treating B cell disorders by this approach is also provided.

## Claims

### Claim 1

A method of augmenting B cell depletion in a mammal suffering from a B cell disorder, comprising administering to the mammal, one or more B cell mobilizing agents and a therapeutically effective amount of one or more B cell depleting agents, wherein the B cell mobilizing agent is an α4 integrin antagonist antibody, or a biologically active fragment thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the α4 integrin antagonist is an antagonist of α4β1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the α4 integrin antagonist is an antagonist of α4β7.

### Claim 4 (depends on 1)

The method of claim 1, wherein the α4 integrin antagonist is a humanized, human, or chimeric antibody, or a biologically active fragment thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the antibody or antibody fragment binds the α4 subunit (CD-49d)

### Claim 6 (depends on 1)

The method of claim 1, wherein the α4 integrin antagonist is natalizumab.

### Claim 7 (depends on 1)

The method of claim 1, wherein the α4 integrin antagonist is the antibody PS/2 produced by the hybridoma ATCC CRL-1911, or a biologically active fragment or a humanized form thereof.

### Claim 8 (depends on 1)

The method of claim 1, wherein the B cell depleting agent is an antagonist of a B cell surface marker.

### Claim 9 (depends on 8)

The method of claim 8, wherein the B cell surface marker is CD20, CD22, or CD54.

### Claim 10 (depends on 9)

The method of claim 9, wherein the B cell surface marker is CD20.

### Claim 11 (depends on 10)

The method of claim 10, wherein the B cell depleting agent is an antibody that binds CD20.

### Claim 12 (depends on 11)

The method of claim 11, wherein the antibody is rituximab.

### Claim 13 (depends on 11)

The method of claim 11, wherein the antibody that binds CD20 is a humanized antibody.

### Claim 14 (depends on 13)

The method of claim 13, wherein the humanized antibody is selected from the group of humanized 2H7.v16, v31, v114, v138, v477, v588, v511, and antibody that comprises the amino acid sequence of SEQ ID NO. 29 and SEQ ID NO. 30 as variable light and variable heavy chain, respectively.

### Claim 15 (depends on 11)

The method of claim 11, wherein the antibody is a human or chimeric antibody.

### Claim 16 (depends on 1)

The method of claim 1, wherein the B cell mobilizing agent and the B cell depleting agent are administered concurrently or sequentially.
